ALZHEIMER'S

An atlas showing how Alzheimer's changes individual brain cells could help researchers find new treatments for the disease.

The Alzheimer's Brain Bus is out on the road and it's going to be part of a bilingual community event.

Medicare recipients will get a premium reduction — but not until next year.

Medicare recipients will get a premium reduction — but not until next year — reflecting what Health and Human Services Secretary Xavier Becerra said Friday was an overestimate in costs of covering an expensive and controversial new Alzheimer's drug. Becerra’s statement said the 2022 premium should be adjusted downward but legal and operational hurdles prevented officials from doing that in the middle of the year. Medicare Part B premiums jumped by $22 a month, to $170.10, for 2022, in part because of the cost of the drug Aduhelm, which was approved despite weak evidence that it could slow the progression of Alzheimer's.

According to researchers of one clinical trial, Asian American and Pacific Islanders make up fewer than 5% of all Alzheimer's research participants.

Aduhelm is the first treatment approved in the country to slow cognitive decline in those living with Alzheimer's. Doctors have refused to prescribe it, given the lack of data and evidence behind it.

Charities are disappointed but regulators say there is still little evidence of the drug's benefit.

Dr. James Galvin, the Director of the University of Miami Miller School of Medicine’s Comprehensive Center for Brain Health, describes how the new center’s goal is to better treat and prevent degenerative brain diseases like Alzheimer’s and Lewy Body Dementia through research studies and seeing patients. Bobbi Rutt is one of those patients.

Dr. Daniel Gibbs writes about how, after spending his career caring for patients with Alzheimer's, he has now moved to studying the disease from the perspective of a patient himself.

Brigham and Women's Hospital in Boston, Massachusetts is beginning human trials on the vaccine aimed at preventing and slowing Alzheimer's.

Sixteen participants will receive two doses of the vaccine one week apart.

Officials say a new Alzheimer's drug is responsible for about half of that.

The annual event raises hundreds of thousands of dollars for Alzheimer's research.

Medicare's “Part B” outpatient premium will jump by $21.60 next year, one of the largest increases ever. Officials said Friday a new Alzheimer's drug is responsible for about half of that. The increase guarantees that health care will gobble up a big chunk of the recently announced Social Security cost-of-living allowance, a boost that had worked out to $92 a month for the average retired worker, intended to help cover rising prices for gas and food that are pinching seniors.

A new Alzheimer's drug isn't reaching many patients. Doctors say reasons include its high cost, and lingering questions about its effectiveness.

Weeks after the Food and Drug Administration approved the Alzheimer's drug Aduhelm, doctors are struggling to figure out who should get the drug and how to use it safely.

Some patient's who've had COVID-19 develop symptoms resembling early Alzheimer's. Researchers are trying to figure out whether these people are more likely to develop the disease itself.

Acting FDA Commissioner Dr. Janet Woodcock pushed back against questions from a journalist about the approval of Biogen's Alzheimer's medication, Aduhelm.

Research shows how small changes in the way you drive could expose preclinical signs of disease.

The acting head of the Food and Drug Administration is calling for a government investigation into highly unusual contacts between her agency’s drug reviewers and the maker of a controversial new Alzheimer’s drug.

Biogen shares fell on Friday after the head of the Food and Drug Administration called for an investigation into the recent approval of the company's Alzheimer's drug, Aduhelm. In a letter dated and made public Friday, Acting FDA Commissioner Dr. Janet Woodcock asked the independent Office of the Inspector General to investigate interactions between the U.S. agency and Biogen representatives prior to the drug's approval on June 7. But the FDA's decision was controversial as it was a departure from the advice of its independent panel of outside experts, who unexpectedly declined to endorse the drug last fall, citing unconvincing data. Federal regulators have faced intense pressure from friends and family members of Alzheimer's patients asking to fast-track the drug, scientifically known as aducanumab. STAT News and other media outlets have since reported the controversial ways FDA officials worked with biogen executives to get the drug on the market, including using a regulatory shortcut to gain approval.

The label now says the drug is only intended for patients in early stages of the disease – not millions of others with more advanced Alzheimer's.

Featuring splurge-worthy items to feed your design obsession Originally Appeared on Architectural Digest

Speaking on Thursday during a House panel on voting, former Attorney General Eric Holder said he could support voter ID laws, if in those rules “you expand the number of things that somebody can use to prove they are who they claim to be.”

At $56,000 per year, Aduhelm "could be a real budget-buster" for the government health program, some experts say.

Biogen said it is charging $56,000 for an annual course of the new treatment, higher than the $10,000 to $25,000 price some Wall Street analysts were expecting.

"Desperation should drive funding for Alzheimer's research, it should not drive the interpretation of scientific evidence," Karlawish said.

Government health officials have approved the first drug that they say may help slow Alzheimer’s disease.

Government health officials on Monday approved the first new drug for Alzheimer’s disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated treatment hasn’t been shown to help slow the brain-destroying disease. The Food and Drug Administration approved the drug from Biogen based on study results showing it seemed “reasonably likely” to benefit Alzheimer's patients. The new drug, which Biogen developed with Japan’s Eisai Co., did not reverse mental decline, only slowing it in one study.

An experimental medicine seems to ease symptoms of Fragile X syndrome, a genetic disorder that is the most common inherited cause of intellectual disabilities and autism.

Frontotemporal dementia is a cruel disease. This week on 60 Minutes, correspondent Bill Whitaker reports on frontotemporal dementia. She was 61 years old when she began to notice the signs of frontotemporal dementia. Mark Johnson, 40, has the behavioral variant of frontotemporal dementia. To watch Bill Whitaker's 60 Minutes report on frontotemporal dementia, click here.

(CNN) - A new study finds personalized lifestyle interventions not only stopped cognitive decline in people at risk for Alzheimer's, but actually increased their memory and thinking skills within 18 months. "This is the first study in a real-world clinic setting showing individualized clinical management may improve cognitive function and also reduce Alzheimer's and cardiovascular risk," Isaacson said. The study was published Wednesday in the journal "Alzheimer's and Dementia: The Journal of the Alzheimer's Association." "Our study was designed to look at the effects of lifestyle intervention on cognitive function," Isaacson said. The study was not designed to prevent Alzheimer's, only to see if lifestyle changes affected cognitive function.

Biotech stocks surged after Biogen announced plans to revive its Alzheimer's drug aducanumab. Shares of Biogen are up more than 25% and tracking for one of their best days on record ever after the company said it was once again seeking regulatory approval for its Alzheimer's drug. But given the drug trial's history, the Street isn't completely convinced that the outcome will be different this time around. But he also said that if the drug were successful it could "completely change the profile of the company." Following the nearly 30% gain on Tuesday, shares of Biogen were trading around $285.

Shares of Biogen soared nearly 30% on Tuesday after the drugmaker announced it was seeking regulatory approval for an Alzheimer's drug, aducanumab, it said it was giving up on earlier this year. "It would be the biggest drug ever," CNBC's Jim Cramer said on "Squawk on the Street." The announcement comes just months after Biogen discontinued clinical studies of the same drug following a data analysis that did not achieve its objective. Biogen erased its entire 25% year-to-date decline when it said a new analysis of a larger dataset showed that aducanumab "reduced clinical decline in patients with early Alzheimer's disease." Patients who received the drug "experienced significant benefits on measures of cognition and function such as memory, orientation, and language."

Subjects were randomized to 12 months of aerobic exercise or stretching and toning. Both aerobic and stretching may prevent or slow cognitive decline, according to the researchers, but aerobic exercise had more benefits on reducing hippocampal shrinkage than stretching. But MRI and PET imaging showed those who did aerobic exercise had slower degeneration in the hippocampus than those who did flexibility training. "The brains of participants with amyloid responded more to the aerobic exercise than the others," Zhang said. "Most physicians believe in the power of exercise to support overall brain health, but fewer believe that exercise can specifically impact people with early Alzheimer's," Isaacson said.

Untangling the Facebook data scandal, Inside MIT's "Future Factory," For better or worse: Living with Alzheimer's Lesley Stahl reports on Aleksandr Kogan, the link between Facebook and Cambridge Analytica; then, Scott Pelley goes inside MIT's "Future Factory"; and, for better or worse, living with Alzheimer's

In 2002, Nancy Reagan spoke candidly with Mike Wallace about her husband's battle with Alzheimer's. At the time, Reagan was 91 and in the advanced stages of the disease.

A new study from Duke University suggests women at risk for Alzheimer's face a steeper decline than men. CBS News chief medical correspondent Dr. Jon LaPook explains.

Pope slams Vatican leaders in Christmas message Pope Francis turned the traditional Christmas greeting to cardinals, bishops and priests into a catalog of sins he hoped would be atoned for in the new year. Francis castigated what he called "spiritual Alzheimer's" that made the clergy forget they're supposed to be joyful men of God. Allen Pizzey reports.

Siblings swim English Channel for Alzheimer's awareness Devin, Dustin and Danielle Wahl could be the first trio of siblings to swim across the English Channel at the same time. They're doing it in part to raise awareness about Alzheimer's, a disease that affected their loved ones. Norah O'Donnell reports.

New test may help detect Alzheimer's earlier More than 5 million people in the U.S. are living with Alzheimer's. Now British researchers say they have developed a blood test that could reveal early changes in the brain related to the disease - before a patient has symptoms. CBS News' Alphonso Van Marsh reports.